CSBTF (Kuros Biosciences) Owner Earnings per Share (TTM): -0.30 (As of Dec. 2025)


CSBTF Kuros Biosciences Ltd CSBTF
72 GF Score
Price $25.57
GF Value $54.65
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Owner Earnings per Share (TTM)?

Kuros Biosciences CSBTF 72 Owner Earnings per Share (TTM) is -0.30 as of Dec. 2025. GuruFocus rates CSBTF with a GF Score™ of 72/100 and a GF Value™ of $54.65 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 312 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 320512.5% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Kuros Biosciences's Owner Earnings per Share (TTM) ended in Dec. 2025 was $-0.30. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Kuros Biosciences's Owner Earnings per Share (TTM) or its related term are showing as below:



CSBTF's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 24.695
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Kuros Biosciences's Earnings per Share (Diluted) for the six months ended in Dec. 2025 was $0.14. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.09. It's PE Ratio (TTM) ratio for today is 287.30.

Kuros Biosciences's EPS without NRI for the six months ended in Dec. 2025 was $0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.08. It's PE Ratio without NRI ratio for today is 336.44.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Kuros Biosciences Owner Earnings per Share (TTM) Related Terms


Kuros Biosciences Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Kuros Biosciences's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuros Biosciences Owner Earnings per Share (TTM) Chart

Kuros Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.52 -0.34 -0.19 -0.35

Kuros Biosciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 0.00 -0.19 0.00 -0.35

CSBTF vs ABT, SYK, MDT: Owner Earnings per Share (TTM) Comparison

For the Medical Devices subindustry, Kuros Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuros Biosciences Price-to-Owner-Earnings vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Price-to-Owner-Earnings falls into.


CSBTF
72GF Score
Kuros Biosciences Ltd CSBTF
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuros Biosciences Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Kuros Biosciences's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 3.2
Depreciation, Depletion and Amortization 4.2
Change In Deferred Tax 0.0
5Y Average of Maintenance Capital Expenditure 0.6
Change In Working Capital -19.8
Shares Outstanding (Diluted Average) 41.4

1. Start with "Net Income" from income statement. Kuros Biosciences's Net Income for the trailing twelve months (TTM) ended in Dec. 2025 was $3.2 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Kuros Biosciences's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2025 was $4.2 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Kuros Biosciences's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2025 was $0.0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $0.6 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Kuros Biosciences's 5-Year Average Maintenance Capital Expenditure = $0.6 Mil

5. "Change In Working Capital" is from cashflow statement. Kuros Biosciences's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2025 was $-19.8 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Kuros Biosciences's Shares Outstanding (Diluted Average) for the months ended in Dec. 2025 was 41.387 Mil.

Kuros Biosciences's Onwer Earnings Per Share for Dec. 2025 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 3.201 +4.231+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.648+-19.757)/41.387
=-0.30

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=25.5696/-0.30
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -0.30 mean?
Kuros Biosciences (CSBTF) has a Owner Earnings per Share (TTM) of -0.30 as of Dec. 2025. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Kuros Biosciences. According to the industry distribution chart, Kuros Biosciences ranks #999999 out of 312 companies in the Medical Devices & Instruments industry.
Is Kuros Biosciences' Owner Earnings per Share (TTM) too high?
Kuros Biosciences' current Owner Earnings per Share (TTM) is -0.30. Based on the distribution chart, Kuros Biosciences ranks #999999 out of 312 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Owner Earnings per Share (TTM) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #999999 out of 312 companies for Owner Earnings per Share (TTM). This places Kuros Biosciences in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Medical Devices & Instruments company?
The median Owner Earnings per Share (TTM) among Medical Devices & Instruments companies is 24.70, based on 312 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Kuros Biosciences. For the Medical Devices & Instruments industry, the median Owner Earnings per Share (TTM) is 24.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Owner Earnings per Share (TTM) is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.65, compared to a current price of $25.57 — trading 53.2% below its estimated fair value. The current Owner Earnings per Share (TTM) is -0.30. Kuros Biosciences' overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Owner Earnings per Share (TTM) is -0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $25.57 is trading 53.2% below its estimated GF Value™ of $54.65. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Owner Earnings per Share (TTM): -0.30
  • GF Value™: $54.65 vs. price of $25.57 (53.2% below fair value)
  • GF Score™: 72/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
72GF Score

Get the complete analysis for CSBTF

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.57
Price
$54.65
GF Value